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The Relationship between Statins and Diabetes:
Is There Truth to the Findings?
By Deirdre Delea, PharmD
PGY1 Pharmacy Practice Resident
HMG-CoA reductase inhibitors
are cholesterol lowering medications collectively referred to as
statins. These medications include the following: atorvastatin
(Lipitor®), simvastatin (Zocor®),
rosuvastatin (Crestor®), pravastatin (Pravachol®), lovastatin
(Mevacor®), and fluvastatin
(Lescol®). Statins are the most
commonly used medications for
the treatment of high cholesterol
and are well known for their
ability to reduce low-density
lipoprotein (LDL) concentrations.
In addition to their cholesterol
lowering effects, statins have
also been found to produce additional beneficial effects, known
as pleiotropic effects.1 Pleiotropic effects cause antiinflammatory, anti-oxidative and
anti-atherogenic actions within
the body.1 While much is known
about the way statins work
within the body, the full extent
of the direct and indirect effects
produced by statins on the body
and its cells is unknown at this
time. This uncertainty includes
the effect statins have on glucose
uptake and insulin resistance.

A recent large-scale trial involving the use of rosuvastatin in apparently healthy adults without
high cholesterol, the JUPITER
trial, has raised concerns about
whether statin therapy increases
the risk for the development of
diabetes.2 In the JUPITER trial,
no difference was found during
the follow-up period in fasting
blood glucose concentrations or
newly diagnosed glycosuria between patients treated with rosuvastatin and those receiving placebo, and there was a minimal difference between groups in terms
of the median glycated hemoglobin values (HgbA1c).2 However,
physician-reported diabetes was
found more frequently in patients
who were treated with rosuvastatin than those who received placebo.2
Furthermore, there is a case report
of a 48-year-old Japanese man
suggesting a link between use of
statin therapy and the development of diabetes.3 The patient appeared to develop diabetes requiring insulin treatment within 4
months of beginning therapy with
atorvastatin.3 Shortly after atorvastatin therapy was discontinued,
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his diabetes appeared to go into
remission and insulin therapy was
discontinued.3 He was then rechallenged with statin therapy using pravastatin instead of atorvastatin.3 Again, within 4 months of
statin initiation, his fasting blood
glucose and HgbA1c values worsened.3 Finally, once pravastatin
therapy was discontinued, his labs
normalized.3 This case report appears to add strength to the theory
that statin use may increase the
risk for the development of diabetes.
However, many clinical studies
involving statins have not reported
an increase in the rate of participants developing diabetes. Furthermore, patients with type 2 diabetes frequently have high cholesterol and are often treated with
statins. These agents have been
found to have a beneficial effect
in diabetic patients, leading to
lower cholesterol levels and a reduction in cardiovascular events.3
Therefore, the data regarding
whether statins are harmful or
beneficial with respect to their effects on diabetes is conflicting.
One explanation for the variation
of results related to diabetes and
statin use may be partially explained by a study performed by
Mauser and colleagues. This study
looked at the ability of atorvastatin to modify endocrine function
and inhibit glucose uptake in fat
cells, or adipocytes.1 The authors
investigated insulin-induced glucose uptake in two types of fat
cells, fully-differentiated white
adipocytes and less-differentiated
brown adipocytes.1 Treatment of
the white adipocytes with atorvastatin resulted in a dose-dependent
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decrease in insulin-induced glucose uptake.1 This induced insulin resistance was only seen in
insulin
sensitive,
fullydifferentiated adipocytes and not
in previously insulin-resistant
adipocytes.1 From these findings, the authors concluded that
atorvastatin has differing effects
on different types of fat cells.1
Adipocytes that are still differentiating appear to be less likely to
develop insulin resistance caused
by atorvastatin, while adipocytes
that are fully differentiated appear to be more likely to develop
insulin resistance.1 The number
of different types of cells within
the body may determine the
overall effect that a statin has on
glucose metabolism.1 Patients
with a greater number of differentiating adipocytes (eg, obese
patients) may have a different
response to statin therapy than
patients with mostly fullydifferentiated adipocytes.1 This
study suggests that statin therapy
may be associated with increased glucose resistance in
thinner patients, possibly leading
to higher blood glucose concentrations in these individuals.1
Alternatively, statin therapy in
obese patients may result in less
insulin resistance and possibly
even increased insulin sensitivity, resulting in lower blood glucose concentrations in such patients.1
Another possible reason for the
variation in the effects of statins
on diabetes may be the result of
differences in the ability of the
statins to enter cells within the
body. A study by Takaguri and
colleagues looked at the effects

of atorvastatin and pravastatin on
glucose uptake by fat cells.5 This
study found that atorvastatin significantly
decreased
insulinstimulated glucose uptake in fat
cells, whereas pravastatin did not
cause similar decrease to occur.5
The authors concluded that the
difference in action between these
two statins was related to a difference between their capability to
enter cells within the body and
modify the uptake of glucose with
the cell.5 Atorvastatin is lipophilic, which means it can easily
enter any cell within the body and
decrease glucose uptake in these
cells.5 Pravastatin is hydrophilic
and it cannot easily enter any cells
found outside of the liver.5 Therefore, the use of lipophilic statins
may cause a much greater decrease in glucose uptake, and consequently a greater increase in serum glucose concentration, than
the use of hydrophilic statins.
The effect of statins on glucose
metabolism is still controversial.
The exact mechanism of action of
statins and how insulin function is
improved or worsened during
statin therapy is still unclear.
However, it does appear that statins may have the potential to both
increase and decrease insulin sensitivity, and subsequently serum
glucose concentrations. Therefore,
caution may be warranted in the
initiation of statin therapy in individuals without high cholesterol.
References available upon request.
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Did You Know…
Drug Interaction between Cyclosporine and the Statins
By Ashley N. Lewis, PharmD
PGY2 Drug Information Resident
There has been a recent report of rhabdomyolysis in a patient at MUSC receiving concomitant therapy with
a HMG-CoA reductase inhibitor (statin) and cyclosporine (Neoral®, Gengraf®, Sandimmune®). The drugdrug interaction between cyclosporine and statins can lead to serious adverse effects, yet this potential interaction is sometimes overlooked. This may be especially important in the transplant population, as the use
of statins has increased in transplant recipients. The interaction between statins and cyclosporine has been
shown to lead to severe adverse effects, including rhabdomyolysis and renal failure.1
Cyclosporine, as well as atorvastatin (Lipitor®), lovastatin (Mevacor®), simvastatin (Zocor®), rosuvastatin
(Crestor®), and pravastatin (Pravachol®), are metabolized by cytochrome (CYP) 450 3A4. A combination
of cyclosporine with the above statins has been reported to induce rhabdomyolysis; however, this has not
been reported with fluvastatin (Lescol®), most likely because it is primarily metabolized by CYP2C9.1-5 In
addition, pharmacokinetic studies have shown that the area under the curve (AUC) and maximum concentration (Cmax) of pravastatin, simvastatin, lovastatin, atorvastatin, and fluvastatin are increased when they
are administered to transplant patients receiving cyclosporine.1-5
Even though cyclosporine can increase statin concentrations, there is evidence to suggest that statins do not
increase systemic concentrations of cyclosporine.1,4 In patients receiving concurrent statins and cyclosporine, a small, clinically insignificant decrease in cyclosporine concentrations has been shown in several studies.1,4 However, considering the narrow therapeutic range of cyclosporine, it is advisable to intensify cyclosporine monitoring at the initiation of statin therapy or during dosage adjustments.1-5
If concomitant therapy with cyclosporine is required, consider lower initial and maintenance doses of
statins. Limit atorvastatin, pravastatin, and simvastatin to a maximum dose of 10 mg daily. Lovastatin
should not exceed 20 mg daily, and rosuvastatin should not exceed 5 mg daily.1,3 Patients receiving concomitant therapy should be monitored for signs and symptoms of myopathy and rhabdomyolysis, such as
muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during upward
dosage titration of either drug. If myopathy or rhabdomyolysis is diagnosed or suspected, monitor creatine
kinase (CK) concentrations and temporarily withhold or discontinue statin use if CK concentrations show a
noticeable increase.2,3,5
Fluvastatin should be considered as an option for lipid-lowering therapy in these patients, as studies have
indicated that fluvastatin 20 mg and 40 mg daily may be safe in treating renal-transplant patients who are
also taking cyclosporine.6,7 Bile acid sequestrants may also be an option for lipid-lowering therapy in patients receiving cyclosporine, as there seems to be no interactions between these agents; however, there are
limited data to support this recommendation because these agents do not appear to interact.
In conclusion, the incidence of post-transplant dyslipidemia is higher than dyslipidemia in the general population, which has led to an increased use of statins in transplant recipients.1,3 Cyclosporine-treated patients
should receive dosages of statins in the lower dosage range, fluvastatin, or possibly bile acid sequestrants.
In addition, they should be monitored for signs and symptoms of rhabdomyolysis upon initiation or dosage
increase of a statin.1-4
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FORMULARY UPDATE FOR FEBRUARY 2009
In February 2009, the Pharmacy
and Therapeutics Committee approved the actions listed below.
The formulary effective date was
March 16, 2009.
LINE EXTENSIONS
▪ Dopamine 400 mg/ D5W
[250 ml premix]
▪ Hepatitis B vaccine (Energix-B®)
prefilled syringe
▪ Pentacel® vaccine
▪ Rabies immune globulin
(HyperRab® S/D) 150 units/mL
▪ Rabies vaccine (RabAvert®)
single-dose vial
DELETIONS
▪ Clioquinolol/hydrocortisone
(Vioform®HC) 3%/1% cream
▪ Vitamin A 15,000 unit capsules
▪ Rabies immune globulin (Imogam®
Rabies-HT) 150 units/mL
▪ Rabies vaccine (Imovax® Rabies)
single-dose vial
▪ Guaifenesin/codeine 200 mg-20
mg/10 mL unit-dose caps
POLICIES/PROTOCOLS
The following anticoagulation management protocols have been revised
and will be added to the clinician order forms section: PE/DVT Unfractionated Heparin Protocol, Cardiology Unfractionated Heparin Protocol,
Vascular Surgery Unfractionated
Heparin Protocol, Neuro Unfractionated Heparin Protocol, ABIOMED
Unfractionated Heparin Protocol, and
the Anticoagulation Reversal Protocol.
The next meeting of the Pharmacy
and Therapeutics Committee will be
on March 31, 2009.

LEVALBUTEROL (XOPENEX®)
AUTOMATIC THERAPEUTIC SUBSTITUTION
Several studies have been performed that evaluated the differing effects of levalbuterol and racemic albuterol on heart rate, with inconclusive results. Although some clinical trials do show a statistically
significant difference, this difference was an increase of approximately 2 to 3 beats per minute on average. The use of levalbuterol
means a substantial increase in expenditures as compared with equivalent doses of albuterol. The American Academy of Pediatrics and the
American Association of Family Physicians state there is similar efficacy between albuterol and levalbuterol. Therefore, as of March 16,
the ATS protocol for levalbuterol, seen in Tables 1 and 2, has been
revised to include/accommodate more dosing frequencies.
Table 1. Dosing Conversions for Levalbuterol to Albuterol
Converted To

Order Written As
Inhalation Solution
Levalbuterol 0.31 mg

Albuterol sulfate 0.63 mg

Levalbuterol 0.63 mg

Albuterol sulfate 1.25 mg

Levalbuterol 1.25 mg

Albuterol sulfate 2.5 mg

Metered Dose Inhaler (MDI)
The number of puffs are the same
(the mg per actuation of levalbuterol is 50% of albuterol)
Table 2. Frequency Conversion for Levalbuterol to Albuterol*
Order Written As

Converted To

Q2 or Q3h

Q4h

Q4h

Q4h

Q6h

Q6h

Q8h

Q8h

Q2h or Q3h PRN

Q4h PRN

Q4h PRN

Q4h PRN

Q6h PRN

Q6h PRN

Q8h PRN

Q8h PRN

*Note that the FDA labeled frequency for levalbuterol and albuterol is Q6h-Q8h

